Oral Therapy Teriflunomide (Aubagio?(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis
Paris (ots/PRNewswire) - - New findings from the pivotal TEMSO Phase III study presented today at the joint ECTRIMS / ACTRIMS Congress - - U.S. FDA Accepts New Drug Application for Teriflunomide for relapsing forms of MS - Sanofi and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide ...